Alector Reports Second Quarter 2022 Financial Results and Provides Business Update
Alector, Inc. (ALEC)
Last alector, inc. earnings: 3/24 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Investigational New Drug Application submitted for AL044, a novel drug candidate targeting an Alzheimer’s disease risk gene Expanding clinical sites to drive additional enrollment in the INFRONT-3 pivotal study for latozinemab (AL001) and enrollment continues in the INVOKE-2 Phase 2 study for AL002 Peter Heutink, Ph.D., to join company as Chief Scientific Officer John Maraganore appointed as strategic advisor $808.9 million in cash, cash equivalents and investments provide runway into H2-2024 SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported second quarter 2022 financial results and recent portfolio and business updates. As of June 30, 2022, Alector’s cash, cash equivalents and investments totaled $808.9 million. Commentary on the Quarter: “We continue to make significant progress in building our pipeline of novel immuno-neurology and immuno-oncology d
Show less
Read more
Impact Snapshot
Event Time:
ALEC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALEC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALEC alerts
High impacting Alector, Inc. news events
Weekly update
A roundup of the hottest topics
ALEC
News
- The past five years for Alector (NASDAQ:ALEC) investors has not been profitable [Yahoo! Finance]Yahoo! Finance
- Alector, Inc. (NASDAQ: ALEC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $41.00 price target on the stock.MarketBeat
- Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Alector to Participate in Upcoming Healthcare ConferencesGlobeNewswire
- Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
ALEC
Earnings
- 2/27/24 - Beat
ALEC
Analyst Actions
- 2/28/24 - HC Wainwright
ALEC
Sec Filings
- 3/21/24 - Form 4
- 3/21/24 - Form 4
- 3/21/24 - Form 3
- ALEC's page on the SEC website